Canopy Growth Corporation (CGC)
NASDAQ: CGC · Real-Time Price · USD
1.170
-0.020 (-1.68%)
Jan 5, 2026, 9:41 AM EST - Market open
Canopy Growth Revenue
Canopy Growth had revenue of 66.68M CAD in the quarter ending September 30, 2025, with 5.86% growth. This brings the company's revenue in the last twelve months to 278.61M, down -0.67% year-over-year. In the fiscal year ending March 31, 2025, Canopy Growth had annual revenue of 269.00M, down -9.47%.
Revenue (ttm)
278.61M CAD
Revenue Growth
-0.67%
P/S Ratio
2.04
Revenue / Employee
290,218 CAD
Employees
960
Market Cap
408.80M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 269.00M | -28.15M | -9.47% |
| Mar 31, 2024 | 297.15M | -36.11M | -10.83% |
| Mar 31, 2023 | 333.25M | -142.45M | -29.94% |
| Mar 31, 2022 | 475.70M | -70.95M | -12.98% |
| Mar 31, 2021 | 546.65M | 147.88M | 37.08% |
| Mar 31, 2020 | 398.77M | 172.43M | 76.18% |
| Mar 31, 2019 | 226.34M | 148.39M | 190.37% |
| Mar 31, 2018 | 77.95M | - | - |
| Mar 31, 2017 | - | - | - |
| Mar 31, 2016 | - | - | - |
| Mar 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CGC News
- 6 days ago - Trump Is Warming to Cannabis, but Investors Aren't Impressed - WSJ
- 16 days ago - Inside the dealmaking that pushed Trump to reclassify pot, expand access - CNBC
- 16 days ago - After Trump's move to reclassify cannabis, here's what Wall Street is thinking - Market Watch
- 17 days ago - Trump just legalized marijuana nationwide — here's why potheads are rejoicing - New York Post
- 17 days ago - Why US banks are still wary of cannabis despite Trump's policy shift - Invezz
- 17 days ago - Cannabis companies face hurdles accessing big banks despite reclassification, experts say - Reuters
- 17 days ago - Donald Trump Has Officially Reclassified Marijuana To A Schedule 3 Substance - MarijuanaStocks
- 17 days ago - Trump signs executive order on marijuana reclassification; cannabis shares rally - Invezz